THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SUPPLY AND RESELLER AGREEMENTSupply and Reseller Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
This Supply and Reseller Agreement (the “AGREEMENT”) is by and between LIFE TECHNOLOGIES CORPORATION (“LTC”), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford Immunotec, Ltd. (“OI”), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, U.K., and is effective as of August 12, 2013 (the “EFFECTIVE DATE”).
AMENDED AND RESTATED SUPPLY AND RESELLER AGREEMENTSupply and Reseller Agreement • March 28th, 2019 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
This Amended and Restated Supply and Reseller Agreement (the "AGREEMENT") is by and between LIFE TECHNOLOGIES CORPORATION ("LTC"), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford Immunotec, Ltd. ("OI"), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, U.K., and is effective as of January 1, 2019 (the "EFFECTIVE DATE").
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIRST AMENDMENT TO SUPPLY AND RESELLER AGREEMENTSupply and Reseller Agreement • April 3rd, 2014 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
This First Amendment (“First Amendment”) to the Supply and Reseller Agreement dated August 12, 2013, is made effective as of March 1, 2014 (the “First Amendment Effective Date”) and is by and between Life Technologies Corporation (“LTC”), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402,USA and Oxford Immunotec, Ltd. (“OI”), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton, Park, Abingdon, Oxfordshire, OX14 4RY, United Kingdom.
SECOND AMENDMENT TO SUPPLY AND RESELLER AGREEMENTSupply and Reseller Agreement • November 1st, 2016 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
This Second Amendment (“Second Amendment”) to the Supply and Reseller Agreement dated August 12, 2013, is made this 26th day of July, 2016 (“Second Amendment Effective Date”), by and between LIFE TECHNOLOGIES CORPORATION, a Delaware corporation, that is a wholly-owned subsidiary Thermo Fisher Scientific, Inc., with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402, USA (“LTC”) and OXFORD IMMUNOTEC, LTD., a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, United Kingdom (“OI”). LTC and OI may be referred to individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO THE AMENDED AND RESTATED SUPPLY AND RESELLER AGREEMENTSupply and Reseller Agreement • November 20th, 2019 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
This First Amendment (“Amendment”) to the Amended and Restated Supply and Reseller Agreement is by and between Life Technologies Corporation (“LTC”), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford Immunotec, Ltd. (“OI”), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX 14 4RZ, U.K., and is effective as of November 5, 2019 (“Amendment Effective Date”).
